Today: August 30, 2015, 1:37 am

INFINITY - IPI-145, Unpartnered, Potent PI3K Inhibitor = Larger Opportunity! - new market research report published
INFINITY - IPI-145, Unpartnered, Potent PI3K Inhibitor = Larger Opportunity! - a new market research report on 2014-03-14 09:19:02
Regaining WW rights of IPI-145 (PI3K-delta, gamma isoform inhibitor, PhI/II, hematological malignancies, inflammation) from Takeda and targeting both hematologic malignancies and inflammation indication has sparked interest in Infinity Pharma (INFI).

Despite limited clinical data in hand, PC and in vitro study demonstrates competitive advantages vs. drugs in pipeline hence the licensing/acquisition chances are bright. Based on PC data, IPI-145 is more potent than Gilead´s PI3K inhibitor Idelalisib (GS1101, PhIII). In a PhI study, IPI-145 has shown rapid onset of clinical activity in CLL/SLL as mono therapy. IPI-145´s Potential not dimmed even as a 3rd/4th...

For more details, please read our report released on 13th February 2013 on INFI titled "IPI-145, Unpartnered, Potent PI3K Inhibitor = Larger Opportunity!"

Click for report details: ..

Browse all Healthcare and Medical Market Research Reports ..

Browse all Healthcare and Medical Company Profile Reports ..

Browse all Latest Market Research Reports ..

About Us is a leading online business information aggregator with over 300,000 market reports and company profiles available to our clients. Our extensive range of reports are sourced from the leading publishers of business information and provide clients with the widest range of information available. In terms of company profiles,’s online database allows clients access to market and corporate information to over 100,000 different companies. We provide clients with a fully indexed database of information where clients can find specific market reports on their niche industry sectors of interest.

Press Information

Published by
Mike King
London: +44 (0) 203 086 8600
Related Articles

Disclaimer: If you have any questions regarding information in this press release please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims the content included in this release.